DOP45: Blood-derived neutrophils give rise to differentially activated populations in the mucosa of active Inflammatory Bowel Disease patientsECCO'24Year: 2024
Authors: Veny, M.(1,2)*;Sanzo-Machuca, A.(1);Corraliza, A.M.(1,2);Strobbe, F.(1,2);Garrido-Trigo, A.(1,2);Gudiño, V.(1,2);Melón-Ardanaz, E.(1,2);Esteller, M.(1,2);Teubel, I.(1,2);Masamunt, M.C.(1,2);Ordás, I.(1,2);Prieto, C.(1,2);Giner, À.(1,2);Martin-Cardona, A.(2,3);Esteve, M.(2,3);Ricart, E.(1,2);Salas, A.(1,2);
(1)Institut d@E@Investigacions Biomèdiques August Pi i Sunyer- IDIBAPS, Inflammatory Bowel Disease Unit, Barcelona, Spain;(2)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Ciberehd, Madrid, Spain;(3)Hospital Universitari Mútua Terrassa- Universitat de Barcelona, Department of Gastroenterology, Terrassa, Spain;
DOP46: Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH studyECCO'24Year: 2024
Authors: Narula, N.(1)*;Peerani, F.(2);Hansen, T.(3);Bessissow, T.(4);Bressler, B.(5);Arun, A.(1);Schmit, M.(6);Castelli, J.A.(1);Marshall, J.K.(1);
(1)McMaster University, Gastroenterology, Hamilton, Canada;(2)University of Alberta, Gastroenterology, Edmonton, Canada;(3)University of Manitoba, Gastroenterology, Winnipeg, Canada;(4)Montreal General Hospital site/McGill University Health Center, Gastroenterology, Montreal, Canada;(5)St. Paul’s Hospital/University of British Colombia, Gastroenterology, Vancouver, Canada;(6)GI Research Institute, Gastroenterology, Vancouver, Canada;Canadian IBD Research Consortium
DOP47: Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatmentECCO'24Year: 2024
Authors: Panaccione, R.(1)*;Melmed, G.Y.(2);Khanna, R.(3);D’Haens, G.(4);Danese, S.(5);Ford, S.(6);Anyanwu, S.I.(6);Garrison, A.(6);Lacerda, A.P.(6);Vermeire, S.(7);
(1)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(2)Cedars-Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute, Los Angeles, United States;(3)University of Western Ontario, Department of Medicine- Robarts Clinical Trials, London, Canada;(4)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(6)AbbVie, Inc., North Chicago, United States;(7)University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
DOP48: Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futilityECCO'24Year: 2024
Authors: Deleu, S.(1)*;Caenepeel, C.(2,3);Vazquez Castellanos, J.F.(4,5);Arnauts, K.(1);Braekeleire, S.(1);Machiels, K.(1);Baert, F.(6);Mana, F.(7);Pouillon, L.(8);Hindryckx, P.(9);Lobaton Ortega , T.(9);Louis, E.(10);Franchimont, D.(11);Verstockt, B.(3,12);Ferrante, M.(1,3);Sabino, J.(3,12);Vieira-Silva, S.(4,13);Falony, G.(4,14);Raes, J.(4,5);Vermeire, S.(1,3);
(1)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and MetabolismCHROMETA, Leuven, Belgium;(3)University Hospital Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium;(5)VIB, Center for Microbiology, Leuven, Belgium;(6)AZ Delta, Department of Gastroenterology and Hepatology, Roeselare, Belgium;(7)University Hospitals Brussel, Department of Gastroenterology and Hepatology, Brussels, Belgium;(8)Imelda Hospital, Department of Gastroenterology and Hepatology, Bonheiden, Belgium;(9)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(10)CHU Liège, Department of Gastroenterology and Hepatology, Liège, Belgium;(11)Erasmus Hospital Brussel, Department of Gastroenterology and Hepatology, Brussels, Belgium;(12)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(13)University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Medical Microbiology and Hygiene and Research Center for Immunotherapy, Mainz, Germany;(14)University Medical Center of the Johannes Gutenberg-University Mainz, - Institute of Medical Microbiology and Hygiene and Research Center for Immunotherapy, Mainz, Germany;
DOP49: Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction studyECCO'24Year: 2024
Authors: Panés, J.(1)*;Dignass, A.(2);Lichtenstein, G.(3);Huang, K.H.(4);Germinaro, M.(4);Houck, N.(4);Han, C.(4);Miao, Y.(4);Zhang, H.(4);Abu Farsakh, N.(5);Patel, B.(6);Owczarek, D.(7);Hisamatsu, T.(8);Sands, B.(9);Bressler, B.(10);
(1)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(2)Department of Medicine I- Agaplesion Markus Hospital- Goethe University, Gastroenterology, Frankfurt, Germany;(3)University of Pennsylvania, Gastroenterology, Philadelphia, United States;(4)Janssen Research & Development- LLC, Gastroenterology, Spring House, United States;(5)King Abdullah University Hospital, Gastroenterology, Irbid, Jordan;(6)Peak Gastroenterology Associates PGA, Gastroenterology, Colorado Springs, United States;(7)Centrum Medyczne PROMED, Gastroenterology, Kraków, Poland;(8)Kyorin University, Gastroenterology, Tokyo, Japan;(9)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(10)University of British Columbia, Gastroenterology, Vancouver, Canada;QUASAR Clinical Investigators
DOP50: PINPOINT: The epidemiology of paediatric-onset Inflammatory Bowel Disease in the United Kingdom – a prospective, national, cohort study.ECCO'24Year: 2024
Authors: Henderson, P.(1)*;Dobson, L.(2);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(2)IBD Registry, Senior Management, London, United Kingdom;PINPOINT Collaborators and the IBD Registry
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort studyECCO'24Year: 2024
Authors: Yang, Y.(1)*;Ludvigsson, J.F.(1,2,3);Forss, A.(1,4);Faucon, A.L.(1,5);Faye, A.S.(6);Olen, O.(7,8,9);Sjölander, A.(1);Carrero, J.J.(1,10);
(1)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(2)Örebro University Hospital, Department of Paediatrics, Örebro, Sweden;(3)Columbia University College of Physicians and Surgeons, Celiac Disease Center- Department of Medicine, New York- NY, United States;(4)Karolinska University Hospital, Gastroenterology Unit- Department of Gastroenterology- Dermatovenereology and Rheumatology, Stockholm, Sweden;(5)Paris-Saclay University, Department of Clinical Epidemiology- Centre for Epidemiology and Population Health, Villejuif, France;(6)New York University Grossman School of Medicine, Department of Medicine and Population Health, New York- NY, United States;(7)Karolinska Institutet, Clinical Epidemiology Division- Department of Medicine Solna, Stockholm, Sweden;(8)Stockholm South General Hospital, Sachs@E@ Children and Youth Hospital, Stockholm, Sweden;(9)Karolinska Institutet, Department of Clinical Science and Education- Södersjukhuset, Stockholm, Sweden;(10)Karolinska Institutet, Division of Nephrology- Department of Clinical Sciences- Danderyd Hospital, Stockholm, Sweden;
DOP52: Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12ECCO'24Year: 2024
Authors: Dignass, A.(1)*;Panés, J.(2);Rubin, D.T.(3);Huang, K.H.G.(4);Germinaro, M.(4);Pandya, D.(4);Han, C.(5);Miao, Y.(6);Zhang, H.(6);Gu, F.(7);Rowbotham, D.(8);Mihaly, E.(9);Bressler, B.(10);Lichtenstein, G.R.(11);Allegretti, J.R.(12);
(1)Agaplesion Markus Hospital, Medicine, Frankfurt, Germany;(2)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Inflammatory Bowel Disease Unit, Barcelona, Spain;(3)University of Chicago Medicine Inflammatory Bowel Disease Center-, Gastroenterology- Hepatology & Nutrition, Chicago, United States;(4)Janssen Research & Development- LLC, Clinical Research GI, Spring House, United States;(5)Janssen Global Services- LLC, Strategic Market Access, Malvern, United States;(6)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(7)Peking University Third Hospital, Gastroenterology, Beijing, China;(8)Auckland City Hospital, Gastroenterology and Hepatology, Auckland, New Zealand;(9)Semmelweis University, Internal Medicine, Budapest, Hungary;(10)University of British Columbia, Gastroenterology, Vancouver, Canada;(11)University of Pennsylvania, Medicine, Philadelphia, United States;(12)Brigham and Women’s Hospital Crohn’s and Colitis Center, Gastroenterology- Hepatology- and Endoscopy, Boston, United States;QUASAR Clinical Investigators
DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn@E@s Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionECCO'24Year: 2024
Authors: Ferrante, M.(1)*;Panaccione, R.(2);Colombel, J.F.(3);Dubinsky, M.(4);Hisamatsu, T.(5);Lindsay, J.O.(6);Song, A.(7);Neimark, E.(7);Zhang, Y.(8);Kligys, K.(9);Crowley, J.(9);Duan, W.R.(10);D’Haens, G.(11);
(1)KU Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;(2)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(3)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology- Department of Medicine-, New York, United States;(4)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Center, New York, United States;(5)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(6)Queen Mary University of London, Centre for Immunobiology- Barts and The London School of Medicine and Dentistry, London, United Kingdom;(7)AbbVie, Clinical Development, North Chicago, United States;(8)AbbVie, Statistics, North Chicago, United States;(9)AbbVie, Medical Affairs, North Chicago, United States;(10)AbbVie, Pharmacovigilance and Patient Safety, North Chicago, United States;(11)University of Amsterdam, Department of Gastroenterology and Hepatology- Amsterdam UMC, Amsterdam, United States;
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapyECCO'24Year: 2024
Authors: Richards , D.(1);Vetter , M.(1);Germinaro , M.(1);Verstockt , B.(2);Atreya , R.(3)*;Panes , J.(4);Sands , B.E.(5);Feagan , B.(6);McRae , B.(7);Cua , D.(1);Branigan , P.(1);Freeman , T.C.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospital Erlangen- Friedrich-Alexander University Erlangen-Nuremberg, Department of Medicine I- Gastroenterology- Endocrinology and Pneumology, Erlangen, Germany;(4)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(5)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology, New York, United States;(6)Alimentev Inc.- Western University, Gastroenterology, London, Canada;(7)Janssen Research & Development LLC, Research & Development, Cambridge, United States;
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysisECCO'24Year: 2024
Authors: Noble, A.(1)*;Adams, A.T.(1,2);Nayak, K.M.(3);Kalla, R.(4);Ventham, N.(5);Cheng, G.(6);Ashton, J.J.(6,7);Hansen, R.(8);Croft, N.(9);Wilson, D.C.(10,11);Ennis, S.(6);Zilbauer, M.(3);Uhlig, H.H.(1,2,12);Satsangi, J.(1);
(1)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Experimental Medicine, Oxford, United Kingdom;(2)University of Oxford, Biomedical Research Centre, Oxford, United Kingdom;(3)University of Cambridge, Department of Paediatrics, Cambridge, United Kingdom;(4)University of Edinburgh, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom;(5)University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom;(6)University of Southampton, Department of Human Genetics and Genomic Medicine, Southampton, United Kingdom;(7)University of Southampton, Department of Paediatric Gastroenterology, Southampton, United Kingdom;(8)University of Dundee, Child Health- Division of Molecular and Clinical Medicine, Dundee, United Kingdom;(9)Queen Mary University of London, Blizard Institute- Faculty of Medicine and Dentistry-, London, United Kingdom;(10)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(11)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;(12)University of Oxford, Department of Paediatrics, Oxford, United Kingdom;
DOP56: Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn@E@s DiseaseECCO'24Year: 2024
Authors: Tavares de Sousa, H.(1,2)*;Ferreira, M.(3,4,5);Gullo, I.(4,5,6,7);Rocha, A.M.(4,5);Oliveira, C.(4,5);Carneiro, F.(4,5,6,7);Magro, F.(8,9,10);
(1)Centro Hospitalar Universitário Algarve, Department of Gastroenterology, Porti, Portugal;(2)University of Algarve, ABC—Algarve Biomedical Center, Faro, Portugal;(3)University of Porto, Computer Science Department- Faculty of Sciences, Porto, Portugal;(4)University of Porto, Instituto de Investigação e Inovação em Saúde i3S, Porto, Portugal;(5)University of Porto, Institute of Molecular Pathology and Immunology- University of Porto IPATIMUP, Porto, Portugal;(6)Faculty of Medicine of the University of Porto, Department of Pathology, Porto, Portugal;(7)São João University Hospital Center, Department of Pathology, Porto, Portugal;(8)Faculty of Medicine of the University of Porto, Unit of Pharmacology and Therapeutics- Department of Biomedicine, Porto, Portugal;(9)Faculty of Medicine of the University of Porto, Cintesis_at_rise, Porto, Portugal;(10)São João University Hospital Center, Department of Gastroenterology, Porto, Portugal;
DOP57: Cystic fibrosis risk variants confer a protective effect against Inflammatory Bowel Disease in large-scale exome sequencing analysisECCO'24Year: 2024
Authors: Yu, M.(1)*;
(1)Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Disorders, Cambridge, United States;
DOP58: Human Leukocyte Antigen drives methylation signatures in primary sclerosing cholangitis but not in IgG4-related sclerosing cholangitis.ECCO'24Year: 2024
Authors: Cabras, S.(1);Adams, A.(1);Noble, A.(1);Motta, R.(1)*;Moron Flores, B.(1);Glapa-Nowak, A.(2);Nowak, J.(2);Geremia, A.(1);Culver, E.(1);Satsangi, J.(1);
(1)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;(2)Poznan University of Medical Sciences, Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan, Poland;
DOP59: Integration of in silico analysis and in vitro functional analysis reveals Tissue Factor Pathway Inhibitor 2 (TFPI2) as a master transcriptional regulator and potential target to impede Infliximab resistance in adult UC patientsECCO'24Year: 2024
Authors: Genua, F.(1)*;Lawal, O.(1);Kel, A.(2,3,4);Tosetto, M.(5);Stack, R.(5); Sheahan, K.(6);Yochum, G.(7,8);Doherty, G.(5);Das, S.(1);
(1)Royal College of Surgeons in Ireland, School of Pharmacy and Biomolecular Sciences PBS, Dublin, Ireland;(2)geneXplain, GmbH, Wolfenbüttel, Germany;(3)BIOSOFT.RU, Llc, Novosibirsk, Russian Federation;(4)Institute of Chemical Biology and Fundamental Medicine, Sb RAS, Novosibirsk, Russian Federation;(5)St. Vincent@E@s University Hospital and School of Medicine- University College Dublin, Centre for Colorectal Disease, Dublin, Ireland;(6)St. Vincent@E@s University Hospital, School of Medicine, Dublin, Ireland;(7)Pennsylvania State Milton S. Hershey Medical Center, Department of Biochemistry and Molecular Biology, Hershey, United States;(8)Pennsylvania State Milton S. Hershey Medical Center, Department of Surgery, Hershey, United States;
DOP60: Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER StudyECCO'24Year: 2024
Authors: Gutiérrez Casbas, A.(1)*;Rodríguez-Lago, I.(2);Marín-Jiménez, I.(3);Plaza, Z.(4);Gratacós, J.(5);Trujillo, E.(6);Pérez-Pampín, E.(7);Barreiro de Acosta, M.(8);Aznar-Esquivel, A.(6);Carrillo, M.(9);García-Vivar, M.L.(10);Muñoz-Villafranca, M.D.C.(11);Ladehesa, L.(12);Iglesias-Flores, E.(13);Merino, C.(14);González-Lama, Y.(15);Arévalo, M.(16);Calvet, X.(17);Brandy-García, A.(18);Izquierdo-Romero, M.(19);Manrique, S.(20);Olmedo, R.(21);García-LLorente, J.F.(22);Zugaza, J.(23);Ros-Vilamajo, I.(24);Rull, N.(25);Pinto-Tasende, J.A.(26);Ucha, P.(27);González, C.(28);Rodríguez-Martín, F.(29);Serrano, S.(30);Domínguez-Alvaro, M.(4);Prado-Galbarro, F.J.(31);Sanz, J.(14);
(1)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology- CIBERehd- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Alicante, Spain;(2)Hospital de Galdakao, Gastroenterology, Bilbao, Spain;(3)Hospital Gregorio Marañón, Gastroenterology, Madrid, Spain;(4)Unidad Investigación Sociedad Española Reumatología, Research, Madrid, Spain;(5)Hospital Universitari Parc Taulí Sabadell, Rheumatology, Sabadell, Spain;(6)Hospital Universitario Canarias, Rheumatology, La Laguna, Spain;(7)Complejo Hospitalario Santiago de Compostela, Rheumatology, Santiago de Compostela, Spain;(8)Complejo Hospitalario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(9)Hospital Universitario Canarias, Gastroenterology, La Laguna, Spain;(10)Hospital de Basurto, Rheumatology, Basurto, Spain;(11)Hospital de Basurto, Gastroenterology, Basurto, Spain;(12)Hospital Universitario Reina Sofía, Rheumatology, Córdoba, Spain;(13)Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain;(14)Hospital Universitario Puerta de Hierro, Rheumatology, Madrid, Spain;(15)Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain;(16)Hospital Parc Taulí, Rheumatology, Sabadell, Spain;(17)Hospital Parc Taulí- UAB, Clinical Biochemestry, Sabadell, Spain;(18)Hospital Cabueñes, Rheumatology, Gijón, Spain;(19)Hospital Cabueñes, Gastroenterology, Gijón, Spain;(20)Hospital Regional de Málaga, Rheumatology, Málaga, Spain;(21)Hospital Regional de Málaga, Gastroenterology, Málaga, Spain;(22)Hospital Galdakao, Rheumatology, Madrid, Spain;(23)Hospital Galdakao, Gastroenterology, Galdakao, Spain;(24)Hospital Universitario Son Llàtzer, Rheumatology, Mallorca, Spain;(25)Hospital Universitario Son Llátzer, Gastroenterology, Mallorca, Spain;(26)Complejo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain;(27)Complejo Hospitalario Universitario A Coruña, Gastroenterology, A Coruña, Spain;(28)Hospital Gregorio Marañón, Rheumatology, Madrid, Spain;(29)Hospital Universitario General Santa Lucia, Rheumatology, Cartagena, Spain;(30)Hospital Universitario General Santa Lucia, Gastroenterology, Cartagena, Spain;(31)Hospital Infantil de Mexico, Bioestadística, Ciudad de México, Mexico;EISER studygroup
DOP61: Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic targetECCO'24Year: 2024
Authors: Acharjee, A.(1,2);Shivaji, U.N.(3,4);Santacroce, G.(5)*;Jeffery, L.(4);Reynolds, G.(6);Majumder, S.(4,5);Akiror, S.(6);Zardo, D.(7);Gkoutos, G.V.(1,2);Iacucci, M.(3,4,5);Amamou, A.(5);Ghosh, S.(5);
(1)Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom;(2)Centre for Health Data Research, University of Birmingham, Birmingham, United Kingdom;(3)Gastroenterology- Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;(4)Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;(5)APC Microbiome Ireland- College of Medicine and Health, University College of Cork, Cork, Ireland;(6)Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, United Kingdom;(7)Department of Pathology, San Bortolo Hospital, Vicenza, Italy;
DOP62: A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative ColitisECCO'24Year: 2024
Authors: Saifuddin, A.(1)*;Cozzetto, D.(2);Pavlidis, P.(3);Hart, A.(4);Powell, N.(2);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, Beckenham, United Kingdom;(2)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(3)King@E@s College London, Gastroenterology, London, United Kingdom;(4)St Mark@E@s Academic Institute, Inflammatory Bowel Disease, Harrow, United Kingdom;
DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.ECCO'24Year: 2024
Authors: Malham, M.(1);Jansson, S.(1)*;Ingels, H.A.S.(2);Jørgensen, M.H.(3);Roed, N.(4);Wewer, A.V.(5);Fox, M.P.(6);
(1)Amager Hvidovre Hospital and Copenhagen IBD Center- University of Copenhagen-, Department of Pediatrics and Adolescent Medicine, Hvidovre, Denmark;(2)Amager Hvidovre Hospital and Copenhagen IBD Center- University of Copenhagen-, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark;(3)Rigshospitalet- University of Copenhagen, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark;(4)University of Copenhagen- Copenhagen, Section of Epidemiology- Department of Public Health, Copenhagen, Denmark;(5)Copenhagen IBD Center- Amager Hvidovre Hospital- University of Copenhagen, Department of Pediatrics and Adolescent Medicine, Hvidovre, Denmark;(6)Boston University School of Public Health, Departments of Epidemiology and Global Health, Boston, United States;
DOP64: Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trialECCO'24Year: 2024
Authors: Raine, T.(1)*;Danese, S.(2);Schreiber, S.(3);Gao, X.(4);Hanauer, S.(5);Torres, J.(6);Kligys, K.(7);Huang, X.(7);Neimark, E.(7);Anschutz, T.(7);Crowley, J.(7);Cross, R.K.(8);
(1)Addenbrooke’s Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)IRCCS Ospedale San Raffaele Hospital and Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(3)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(4)The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(5)Northwestern University, Division of Gastroenterology, Chicago, United States;(6)Hospital Beatriz Ângelo- Universidade de Lisboa- and Hospital da Luz, Division of Gastroenterology, Lisbon, Portugal;(7)AbbVie Inc., Research and Development, North Chicago, United States;(8)University of Maryland School of Medicine, Department of Medicine, Baltimore, United States;